Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTX NASDAQ:FRMM NASDAQ:KYNB NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.21-2.8%$1.05$0.22▼$3.83$107.67M1.811.05 million shs346,554 shsFRMMForum Markets$4.82-1.8%$0.00$1.76▼$174.60$98.81M1.511.11 million shs84,151 shsKYNBKyntra Bio$7.12+0.3%$7.07$4.85▼$12.60$28.82M1.0326,889 shs653 shsPEPGPepGen$1.82-5.5%$3.71$1.01▼$7.80$127.20M2.011.21 million shs143,746 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-3.13%-3.13%+42.86%+20.39%+185.19%FRMMForum Markets-16.07%-4.47%+78.55%+490,999,900.00%+490,999,900.00%KYNBKyntra Bio+0.14%+0.71%+1.28%-9.67%+709,999,900.00%PEPGPepGen+10.29%+22.15%+11.56%-60.69%+34.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.21-2.8%$1.05$0.22▼$3.83$107.67M1.811.05 million shs346,554 shsFRMMForum Markets$4.82-1.8%$0.00$1.76▼$174.60$98.81M1.511.11 million shs84,151 shsKYNBKyntra Bio$7.12+0.3%$7.07$4.85▼$12.60$28.82M1.0326,889 shs653 shsPEPGPepGen$1.82-5.5%$3.71$1.01▼$7.80$127.20M2.011.21 million shs143,746 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-3.13%-3.13%+42.86%+20.39%+185.19%FRMMForum Markets-16.07%-4.47%+78.55%+490,999,900.00%+490,999,900.00%KYNBKyntra Bio+0.14%+0.71%+1.28%-9.67%+709,999,900.00%PEPGPepGen+10.29%+22.15%+11.56%-60.69%+34.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 2.50Moderate Buy$3.33176.63% UpsideFRMMForum Markets 2.00Hold$5.003.71% UpsideKYNBKyntra Bio 2.33HoldN/AN/APEPGPepGen 2.67Moderate Buy$11.80546.93% UpsideCurrent Analyst Ratings BreakdownLatest KYNB, PEPG, CGTX, and FRMM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSpeculative Buy$5.004/2/2026FRMMForum Markets Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)3/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.003/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.002/27/2026KYNBKyntra Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy2/25/2026PEPGPepGen OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$15.002/18/2026PEPGPepGen GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.002/6/2026KYNBKyntra Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/AFRMMForum Markets$6.55M14.95N/AN/A$12.59 per share0.38KYNBKyntra Bio$6.44M4.48N/AN/A($4.20) per share-1.70PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$23.49M-$0.33N/AN/AN/AN/A-104.27%-69.64%5/6/2026 (Estimated)FRMMForum Markets-$450.52M-$39.19N/AN/AN/AN/A-254.74%-132.82%N/AKYNBKyntra Bio$183.45M$45.470.16N/AN/A2,848.19%N/A-34.39%N/APEPGPepGen-$89.65M-$2.41N/AN/AN/AN/A-75.73%-60.42%5/14/2026 (Estimated)Latest KYNB, PEPG, CGTX, and FRMM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PEPGPepGen-$0.31N/AN/AN/AN/AN/A5/6/2026Q1 2026CGTXCognition Therapeutics-$0.06N/AN/AN/A$4.40 millionN/A3/31/2026Q4 2025FRMMForum MarketsN/A-$12.14N/A-$12.24N/A$2.44 million3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/A3/4/2026Q4 2025PEPGPepGen-$0.40-$0.27+$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A3.453.45FRMMForum Markets0.110.330.33KYNBKyntra BioN/A3.393.26PEPGPepGenN/A11.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%FRMMForum Markets4.07%KYNBKyntra Bio72.71%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics14.40%FRMMForum Markets15.10%KYNBKyntra Bio1.98%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2089.35 million76.49 millionNot OptionableFRMMForum Markets720.31 million17.25 millionN/AKYNBKyntra Bio5704.05 million3.97 millionN/APEPGPepGen3069.17 million65.99 millionNot OptionableKYNB, PEPG, CGTX, and FRMM HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPGMay 3 at 5:39 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)April 26, 2026 | theglobeandmail.comStifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)April 26, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 16, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 14, 2026 | globenewswire.comPepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 13, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comPepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some ReliefMarch 31, 2026 | seekingalpha.comPepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseMarch 31, 2026 | biospace.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMarch 31, 2026 | globenewswire.comPepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMarch 31, 2026 | globenewswire.comPepGen crashes after mid-stage trial data for muscle disorder therapyMarch 31, 2026 | msn.comPepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data TranscriptMarch 31, 2026 | seekingalpha.comPepGen stock tumbles 44% on disappointing trial resultsMarch 30, 2026 | za.investing.comStocks to Watch: PepGen, Phreesia, Virgin GalacticMarch 30, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYNB, PEPG, CGTX, and FRMM Company DescriptionsCognition Therapeutics NASDAQ:CGTX$1.20 -0.04 (-2.82%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Forum Markets NASDAQ:FRMM$4.82 -0.09 (-1.81%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.Kyntra Bio NASDAQ:KYNB$7.12 +0.02 (+0.28%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.PepGen NASDAQ:PEPG$1.82 -0.11 (-5.49%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
